REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) CEO Kenneth T. Mills sold 15,000 shares of the business's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.19, for a total transaction of $272,850.00. Following the transaction, the chief executive officer now owns 408,035 shares in the company, valued at approximately $7,422,156.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
REGENXBIO Stock Performance
RGNX stock opened at $17.03 on Thursday. The firm has a 50 day moving average of $20.03 and a 200-day moving average of $17.85. REGENXBIO Inc. has a 12 month low of $11.83 and a 12 month high of $28.80.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.16). REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. The firm had revenue of $22.30 million during the quarter, compared to the consensus estimate of $34.01 million. During the same quarter last year, the business posted ($1.38) earnings per share. REGENXBIO's revenue was down 28.8% compared to the same quarter last year. On average, analysts anticipate that REGENXBIO Inc. will post -3.98 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
From True Market Insiders | Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%...
Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
RGNX has been the topic of a number of research reports. Robert W. Baird boosted their target price on shares of REGENXBIO from $34.00 to $39.00 and gave the company an "outperform" rating in a research report on Wednesday, March 6th. Stifel Nicolaus reiterated a "buy" rating and set a $40.00 target price on shares of REGENXBIO in a research report on Friday, April 12th. Raymond James reiterated an "outperform" rating and set a $45.00 target price on shares of REGENXBIO in a research report on Wednesday, February 21st. SVB Leerink upgraded shares of REGENXBIO from a "market perform" rating to an "outperform" rating and set a $37.00 target price on the stock in a research report on Wednesday, March 6th. Finally, Leerink Partnrs upgraded shares of REGENXBIO from a "market perform" rating to an "outperform" rating in a research report on Wednesday, March 6th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and an average target price of $38.45.
Check Out Our Latest Analysis on RGNX
Hedge Funds Weigh In On REGENXBIO
A number of large investors have recently modified their holdings of RGNX. Captrust Financial Advisors raised its stake in REGENXBIO by 742.1% in the first quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 846 shares in the last quarter. Royal Bank of Canada raised its stake in REGENXBIO by 189.8% in the third quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 915 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in REGENXBIO in the fourth quarter valued at approximately $38,000. PNC Financial Services Group Inc. raised its stake in REGENXBIO by 73.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 746 shares in the last quarter. Finally, Point72 Middle East FZE purchased a new stake in REGENXBIO in the fourth quarter valued at approximately $52,000. 88.08% of the stock is currently owned by institutional investors.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
